Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Product sales, net	$ 167,674	$ 2,257,851	$ 1,979,060	$ 4,173,759
Cost of products sold	55,626	752,183	615,326	1,370,876
Gross profit	112,048	1,505,668	1,363,734	2,802,883
Selling, general and administrative expenses	3,176,768	2,517,970	5,929,580	4,627,023
Research and development expenses	108,170	95,529	215,650	101,875
Total operating expenses	3,284,938	2,613,499	6,145,230	4,728,898
Loss from operations	(3,172,890)	(1,107,831)	(4,781,496)	(1,926,015)
Interest income fees	(4,062)	(2,375)	(8,159)	(3,618)
Change in fair value of derivative liability		12,462		52,722
Loss before provision for income taxes and net of equity investments	(3,176,952)	(1,097,744)	(4,789,655)	(1,876,911)
Provision for income taxes	(1,250)	(14,163)	(1,500)	(18,627)
Loss before equity in net earnings (losses) of equity investments	(3,178,202)	(1,111,907)	(4,791,155)	(1,895,538)
Earnings from China Joint Venture		(58,664)		(49,100)
Net loss	(3,178,202)	(1,053,243)	(4,791,155)	(1,846,437)
Net loss attributable to noncontrolling interests	11,738	11,959	24,476	22,402
Net loss attributable to Milestone Scientific Inc.	$ (3,166,464)	$ (1,041,284)	$ (4,766,679)	$ (1,824,036)
Net loss per share applicable to common stockholders—
Basic (in dollars per share)	$ (0.06)	$ (0.02)	$ (0.09)	$ (0.04)
Diluted (in dollars per share)	$ (0.06)	$ (0.02)	$ (0.09)	$ (0.04)
Weighted average shares outstanding and to be issued—
Basic (in shares)	56,694,793	45,366,237	51,728,806	41,904,581
Diluted (in shares)	56,694,793	45,366,237	51,728,806	41,904,581